HighGravityDataExact Sciences — Aug 6, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001124140-25-000081
Showing in the filing
Multi-year productivity plan annual savings target
“$150 million in annual savings by 2026”
Period
The long term
Measure
Company-defined measure
Source
Prose
All guidance in this release · 11
Multi-year productivity plan annual savings … for the long term
“$150 million in annual savings by 2026”
Total revenue for FY2025
“$3.130 - $3.170 billion”
Screening revenue for FY2025
“$2.440 - $2.470 billion”
Screening
“$2.440 - $2.470 billion”
Precision Oncology revenue for FY2025
“$690 - $700 million”
Precision Oncology
“$690 - $700 million”
Adjusted EBITDA for FY2025
“$455 - $475 million”
Adjusted EBITDA Y/Y growth rate for FY2025
“44%”
Precision Oncology revenue Y/Y growth rate for FY2025
“6%”
Total revenue Y/Y growth rate for FY2025
“14%”
Screening revenue Y/Y growth rate for FY2025
“17%”
Exhibit 99.1 · the passage around this item
… earlier in the release
sspanos@exactsciences.com 608-556-4380 For Immediate Release Exact Sciences Announces Second Quarter 2025 Results Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights • Delivered record total second quarter revenue of $811 million, an increase of 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million • Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $55 million and $25 million, respectively • Entered into an exclusive license agreement with Freenome for blood-based colorectal cancer screening tests • Gained Medicare coverage for Oncodetect TM molecular residual disease and recurrence monitoring test • Announced a multi-year productivity plan targeting $150 million in annual savings by 2026 MADISON, Wis. , August 6, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for the second quarter ended June 30, 2025, compared to $699 million for the same period of 2024. “The Exact Sciences team continues to build momentum, advancing our mission through earlier detection,” said Kevin Conroy, chairman and CEO. “In the second quarter, we delivered answers to more patients than ever driven by strong momentum behind the successful launch of Cologuard Plus, powerful commercial execution, and exceptional customer satisfaction. This progress strengthens our platform and enables us to deliver better outcomes for patients.” Second quarter 2025 financial results For the three-month period ended June 30, 2025, as compared to the same period of 2024 (where applicable): • Total revenue was $811 million, an increase of 16% on a reported and core revenue basis • Screening revenue was $628 million, an increase of 18% • Precision Oncology revenue was $183 million, an increase of 9% • Gross margin was 69%, and adjusted gross margin was 72% • Net loss was $1 million, or $0.
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.